Cardiovascular Drugs and Therapy

, Volume 28, Issue 5, pp 433–439 | Cite as

Sparstolonin B Attenuates Hypoxia-Induced Apoptosis, Necrosis and Inflammation in Cultured Rat Left Ventricular Tissue Slices

  • Qing Liu
  • Jianping Li
  • Shaiban Jubair
  • Dawei Wang
  • Yi Luo
  • Daping Fan
  • Joseph S. Janicki



Ischemia/reperfusion results in tissue damage, a rapid increase in cytokines and chemokines and inflammatory cell infiltration. Herein we investigated the ability of a selective TLR2/4 antagonist, Sparstolonin B (SsnB), to protect rat cultured left ventricular tissue (LV) slices from hypoxic injury by inhibiting the myocardial inflammatory response independent of inflammatory cell infiltration.

Methods and Results

Media Lactate dehydrogenase (LDH) levels were measured to reflect hypoxia-induced cytotoxicity and cell injury with and without SsnB. Incubation with SsnB (15 and 30 μM) significantly reduced by 20 and 40 %, respectively, the amount of LDH released from the hypoxic LV slices. TUNEL staining showed that SsnB significantly attenuated the levels of hypoxia-induced apoptotic cells from 61.5 ± 4.0 to 27.0 ± 2.1 (15 μM SsnB) and 23.5 ± 2.2 (30 μM SsnB) cells/unit area. Similarly, the Periodic Acid-Schiff (PAS) staining of ischemic areas in untreated hypoxic LV slices was increased 17 fold from 0.26 ± 0.09 to 4.41 ± 0.43 %, while in hypoxic slices incubated with 15 and 30 μM of SsnB, the PAS positive ischemic areas were increased by only 6.4 fold to 1.66 ± 0.39 % and 3.8 fold to 1.00 ± 0.22 %, respectively. Rt-PCR confirmed that MCP1 and IL-6 expression during hypoxia was elevated by 2 and 4 fold, respectively, while their up-regulation was significantly inhibited (i.e., <0.7 fold increase) by SsnB.


The selective TLR2/4 antagonist, Sparstolonin B, can substantially protect LV myocardium via its ability to inhibit injury resulting from hypoxic myocardial-generated inflammation. Accordingly SsnB has potential as a therapeutic agent for the attenuation of myocardial ischemia-reperfusion injury.


Myocardial ischemia injury LDH Apoptosis Necrosis Inflammation 



This work was supported by the National Heart, Lung and Blood Institute at the National Institutes of Health (R21-HL-089483 to J.S.J. and R21AT006767 and R01HL116626 to D.F.).


None declared.


  1. 1.
    Eltzschig HK, Eckle T. Ischemia and reperfusion–from mechanism to translation. Nat Med. 2011;17:1391–401.PubMedCrossRefGoogle Scholar
  2. 2.
    Feuerstein GZ, Young PR. Apoptosis in cardiac diseases: stress- and mitogen-activated signaling pathways. Cardiovasc Res. 2000;45:560–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008;88:581–609.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Poth JM, Brodsky K, Ehrentraut H, Grenz A, Eltzschig HK. Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease. J Mol Med. 2013;91:183–93.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Liang Q, Wu Q, Jiang J, Duan J, Wang C, Smith MD, et al. Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties. J Biol Chem. 2011;286:26470–9.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Liang Q, Yu F, Cui X, Duan J, Wu Q, Nagarkatti P, et al. Sparstolonin B suppresses lipopolysaccharide-induced inflammation in human umbilical vein endothelial cells. Arch Pharm Res. 2013.Google Scholar
  7. 7.
    Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res. 2012;110:126–44.PubMedCrossRefGoogle Scholar
  8. 8.
    Peri F, Piazza M. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. Biotechnol Adv. 2012;30:251–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007;13:552–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Patel H, Shaw SG, Shi-Wen X, Abraham D, Baker DM, Tsui JC. Toll-like receptors in ischaemia and its potential role in the pathophysiology of muscle damage in critical limb ischaemia. Cardiol Res Pract. 2012;2012:121237.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Lin E, Freedman JE, Beaulieu LM. Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases. Cardiovasc Ther. 2009;27:117–23.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ, et al. Role of apoptosis in reperfusion injury. Cardiovasc Res. 2004;61:414–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Santini D, Abbate A, Scarpa S, Vasaturo F, Biondi-Zoccai GG, Bussani R, et al. Surviving acute myocardial infarction: survivin expression in viable cardiomyocytes after infarction. J Clin Pathol. 2004;57:1321–4.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Roubille F, Barrere-Lemaire S. Apoptosis following myocardial infarction: cardiomyocytes and beyond. Eur J Clin Invest. 2013.Google Scholar
  15. 15.
    Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005;73:1907–16.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    He Y, Xi J, Zheng H, Zhang Y, Jin Y, Xu Z. Astragaloside IV inhibits oxidative stress-induced mitochondrial permeability transition pore opening by inactivating GSK-3beta via nitric oxide in H9c2 cardiac cells. Oxid Med Cell Longev. 2012;2012:935738.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion–a target for cardioprotection. Cardiovasc Res. 2004;61:372–85.PubMedCrossRefGoogle Scholar
  18. 18.
    Mughal W, Dhingra R, Kirshenbaum LA. Striking a balance: autophagy, apoptosis, and necrosis in a normal and failing heart. Curr Hypertens Rep. 2012;14:540–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Prech M, Marszalek A, Schroder J, Filas V, Lesiak M, Jemielity M, et al. Apoptosis as a mechanism for the elimination of cardiomyocytes after acute myocardial infarction. Am J Cardiol. 2010;105:1240–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Nah DY, Rhee MY. The inflammatory response and cardiac repair after myocardial infarction. Korean Circ J. 2009;39:393–8.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Fahmi A, Smart N, Punn A, Jabr R, Marber M, Heads R. p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation. Cell Signal. 2013;25:898–909.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Yamauchi-Takihara K, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto T. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation. 1995;91:1520–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Bhattacharya K, Farwell K, Huang M, Kempuraj D, Donelan J, Papaliodis D, et al. Mast cell deficient W/Wv mice have lower serum IL-6 and less cardiac tissue necrosis than their normal littermates following myocardial ischemia-reperfusion. Int J Immunopathol Pharmacol. 2007;20:69–74.PubMedGoogle Scholar
  24. 24.
    Liu Q, Wang J, Liang Q, Wang D, Luo Y, Li J, etal. Sparstolonin B attenuates hypoxia-reoxygenation induced cardiomyocye inflammation. Exper Biol Med. 2014;239:376–84Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Qing Liu
    • 1
    • 2
  • Jianping Li
    • 1
  • Shaiban Jubair
    • 1
  • Dawei Wang
    • 2
  • Yi Luo
    • 2
  • Daping Fan
    • 1
  • Joseph S. Janicki
    • 1
  1. 1.Department of Cell Biology and AnatomyUniversity of South Carolina School of MedicineColumbiaUSA
  2. 2.The Second Clinical School of MedicineGuangzhou University of Chinese MedicineGuangzhouChina

Personalised recommendations